Improvement of mortality by long-term E4010 treatment in monocrotaline- induced pulmonary hypertensive rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 748-752

  Kodama, Kohtarou ^a   Adachi, Hideyuki ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLORO 4 METHOXYBENZYL)AMINO 1 (4 HYDROXYPIPERIDINO) 6 PHTHALAZINECARBONITRILE MONOHYDROCHLORIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC AMP; CYCLIC GMP; E 4010; MONOCROTALINE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SURVIVAL;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ATRIAL NATRIURETIC FACTOR; BODY WEIGHT; CALCIUM SIGNALING; CYCLIC AMP; CYCLIC GMP; HYPERTENSION, PULMONARY; LIGANDS; MALE; MONOCROTALINE; NITRIC OXIDE; NITRILES; ORGAN SIZE; PHOSPHODIESTERASE INHIBITORS; PIPERIDINES; RATS; RATS, WISTAR; SURVIVAL RATE;

EID: 0032799030     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Adachi H, Ishihara H and Nagakura T (1998) Effects of a novel phosphodiesterase 5 inhibitor, E4010, on cardiohemodynamics and plasma hormones in a porcine model of heart failure. Naunyn-Schmiedeberg's Arch Pharmacol 358:R638.
2. Adachi H and Nishino M (1998) Coronary artery diameter increase induced by a phosphodiesterase 5 inhibitor, E4021, in conscious pigs. Jpn JPharmacol 77:99-102.
3. Adnot S, Kouyoumdjian C, Defouilloy C, Andrivet P, Sediame S, Herigault R and Fratacci M-D (1993) Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 148:310-316.
4. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD Jr, Shortino D and Crow JW (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334: 296-302.
5. Braner DAV, Fineman JR, Chang R and Soifer SJ (1993) M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 264:H252-H258.
6. Brown L, Miller J, Dagger A and Sernia C (1998) Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. J Cardiovasc Pharmacol 31: 108-115.
7. Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W and Rodman DM (1996) Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 97:172-179.
8. Comini L, Agnoletti G, Panzali A, Mantero G, Pasini E, Gaia G, Albertini A and Ferrari R (1995) Activation of ANP synthesis during congestive heart failure in rats with monocrotaline. Am J Physiol 268:H391-H398.
9. Ghodsi F and Will JA (1981) Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol 240:H149-H155.
10. Hill NS, Klinger JR, Warburton RR, Pietras L and Wrenn DS (1994) Brain natriuretic peptide: Possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 266:L308-L315.
11. Hirata Y, Ishi M, Matsuoka H, Sugimoto T, Iizuka M, Uchida Y, Serizawa T, Sato H, Kohmoto O, Mochizuki T, Sugimoto T, Miyata A, Kangawa K and Matsuo H (1987) Plasma concentrations of α-human atrial natriuretic polypeptide and cyclic GMP in patients with heart disease. Am Heart J 113:1463-1469.
12. Hirata Y, Suzuki E, Hayakawa H, Matsuoka H, Sugimoto T, Kojima M, Kangawa K and Matsuo H (1992) Role of endogenous ANP in sodium excretion in rats with experimental pulmonary hypertension. Am J Physiol 262:H1684-H1689.
13. Ichinose F, Adrie C, Hurford WE and Zapol WM (1995) Prolonged pulmonary vasodilation of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 78:1288-1295.
14. Ishihara H, Adachi H, Kodama K, Suzuki S, Takamura T and Tanaka H (1998) Pharmacological characterization of a novel, potent selective phosphodiesterase 5 inhibitor, E4010. Jpn J Pharmacol 76(Suppl 1):175P.
15. Jougaaaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei C-M, McKinley LJ and Burnett JC Jr (1996) Cardiac secretion of adrenomedullin in human heart failure J Clin Invest 97:2370-2376.
16. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD and Sweeney G (1997) Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. J Pharmacol Exp Ther 283:619-624.
17. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y and Goto K (1993) Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73:887-897.
18. Parker JD, Landzberg JS, Bittl JA, Mirsky I and Colucci WS (1991) Effects of β-adrenergic stimulation with dobutamine on isovolumic relaxation in the normal and failing human left ventricle. Circulation 84:1040-1048.
19. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M and Magnussen H (1994) Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266:L536-L543.
20. Rubin LJ (1992) Primary pulmonary hypertension. Drugs 43:37-43.
21. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S and Saito I (1995) A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 272:825-831.
22. Shimokubo T, Sakata J, Kitamura K, Kangawa K, Matsuo H and Eto T (1995) Augmented adrenomedullin concentrations in right ventricle and plasma of experimental pulmonary hypertension. Life Sci 57:1771-1779.
23. Takahashi T, Kanda T, Imai S, Suzuki T, Kobayashi I and Murata K (1996a) Semotiadil improves survival of rats with monocrotaline-induced pulmonary hypertension: Comparison with diltiazem. Eur J Pharmacol 295:229-234.
24. Takahashi T, Kanda T, Inoue M, Suzuki T, Kobayashi I, Kodama K and Nagai R (1996b) A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci 59:371-377.
25. Terao G (1997) Inhibitory effects of beraprost sodium on the progression of pulmonary hypertension induced by monocrotaline in rats: A comparison with aspirin, nifedipine and enalapril. J Juzen Med Soc 106:312-319.
26. Yamaguchi K, Oka M, Nishino M, Hanasato N, Kira Y and Fukuchi Y (1998) E4021, cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertension. J Jpn Respir Soc 36:23-27.
27. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M and Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203.